Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
The domain specificity of anti-factor VIII (FVIII) inhibitor antibodies was determined in assays using FVIII domains generated by thrombin cleavage or expressed as recombinant polypeptides to neutralise the inhibitor. The results revealed the existence of three major types of inhibitors, and various combinations of these antibodies were found in haemophilic and autoantibody patients. Anti-A2 domain inhibitors prevent normal function of the FVIII/factor IXa (FIXa)/phospholipid complex in an unknown manner. Binding of FVIII to phospholipid and to von Willebrand factor is blocked by anti-C2 domain antibodies, and the binding of FVIII to FIXa is prevented by anti-A3 domain antibodies. A rare type of inhibitor prevents release of activated FVIII from von Willebrand factor (vWf), and another probably interferes with FVIII binding to factor X (FX) because it shares the epitope of a monoclonal antibody with this property.
Scandella
D
D
Holland Laboratory, American Red Cross, Rockville, Md., USA. scandell@usa.redcross.org
D001665:Binding Sites; D000939:Epitopes / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D005169:Factor VIII / Q000276:immunology* / Q000378:metabolism; D006467:Hemophilia A / Q000097:blood / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000097:blood / Q000378:metabolism; D011485:Protein Binding
D000939:Epitopes; D007518:Isoantibodies; D005169:Factor VIII